Theravance COPD drug on track for FDA decision by November

Revefenacin, a nebulized long-acting muscarinic antagonist, has had a checkered past.

The FDA accepted Theravance Biopharma and Mylan’s nebulized chronic obstructive pulmonary disease drug for review, with a PDUFA date of Nov. 13. If cleared, revefenacin would be the first once-daily, nebulized bronchodilator for COPD.

Revefenacin, a nebulized long-acting muscarinic antagonist (LAMA), has had a checkered past—GlaxoSmithKline acquired the rights to revefenacin in 2004 but ditched the candidate after discovering its formulation was incompatible with its proprietary inhaler.

Without missing a beat, Theravance repositioned the drug as a nebulized product and the company now considers this a distinguishing feature.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: AstraZeneca’s triple-hit COPD inhaler meets goals in phase 3, setting up scrap with GlaxoSmithKline

"Today, patients with moderate to severe COPD do not have access to a nebulized LAMA as a treatment option yet. We believe revefenacin, when approved, represents an important advancement in respiratory care by offering a convenient once-daily option for patients and further strengthens Mylan's robust and growing respiratory portfolio," said Mylan President Rajiv Malik, in a statement.

“With positive results in our Phase 3 program, we believe that revefenacin is well positioned to fill this important need," said Rick Winningham, Theravance CEO. "I commend the team at Theravance Biopharma and Mylan for producing a high-quality submission, and we look forward to working with the FDA in its review of our application."

In July, the companies reported 12-month safety data from two phase 3 trials that showed revefenacin has a similar safety profile to Boehringer Ingelheim’s Spiriva; the data followed positive efficacy data from a pair of shorter phase 3 studies.

While Theravance and Mylan pitted their drug against Spiriva, Verona Pharma took a complementary approach—in September, the U.K.-based company unveiled phase 2a data that showed combining its RPL554 with Spiriva improved lung function in patients with COPD.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.